Related Experiment Video
Updated: Feb 6, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Stroke and antiphospholipid syndrome-antiphospholipid antibodies are a risk factor for an ischemic cerebrovascular
Nataša Gašperšič1, Marjan Zaletel2, Jan Kobal2
1Department of Rheumatology, University Medical Centre Ljubljana, Vodnikova 62, SI-1000, Ljubljana, Slovenia. natasa.gaspersic@kclj.si.
Insights
Antiphospholipid antibodies are an independent risk factor for cerebrovascular events (CVEs). In most antiphospholipid syndrome (APS) patients, antiplatelet therapy is sufficient for secondary prevention in the first year after a CVE.
Area of Science:
- Neurology
- Immunology
- Cardiology
Background:
- Cerebrovascular events (CVEs) are a significant health concern.
- The role of antiphospholipid antibodies in CVE development and management is not fully understood.
- Antiphospholipid syndrome (APS) is an autoimmune disorder associated with an increased risk of thrombosis.
Purpose of the Study:
- To determine the frequency of CVE patients meeting laboratory criteria for APS.
- To investigate if persistent antiphospholipid antibodies are a risk factor for CVE.
- To evaluate the efficacy of treatment strategies in the first year post-CVE.
Main Methods:
- Prospective follow-up of 89 acute CVE patients for 1 year.
- Testing sera for lupus anticoagulants, anticardiolipin, anti-β2-glycoprotein I, anti-phosphatidylserine/prothrombin, and anti-annexin V antibodies.
- Analyzing the association between antiphospholipid antibodies and CVE risk, and treatment outcomes.
Main Results:
- 22% of CVE patients met the criteria for APS (definitive or probable).
- Persistent antiphospholipid antibodies were significantly associated with CVE risk (OR, 4.62).
- No significant difference in CVE recurrence was observed between APS-CVE and non-APS-CVE patients on acetyl salicylic acid therapy.
Conclusions:
- Antiphospholipid antibodies are an independent risk factor for CVE.
- Antiplatelet therapy appears sufficient for secondary CVE thromboprophylaxis in most APS patients within the first year post-event.
Abstract:
Testing for antiphospholipid antibodies could be an important part in determining the cause of a cerebrovascular event (CVE). Currently, it is also unknown whether antiphospholipid antibodies represent a risk factor for the development of a CVE and whether the selected therapy options are efficacious. So, this study aimed at (1) determining the frequency of patients experiencing a CVE and fulfilling the laboratory criterion for an antiphospholipid syndrome (APS), (2) investigating whether the persistent presence of antiphospholipid antibodies represented a risk factor for a CVE, and (3) focusing on the efficacy of the selected treatment strategy in the first year after the CVE. Eighty-nine patients with an acute CVE were prospectively followed for 1 year. At least two sera from each were tested for lupus anticoagulants, anticardiolipin, anti-β2-glycoprotein I, anti-phosphatidylserine/prothrombin and anti-annexin V antibodies. Twenty out of eighty-nine (22%) of CVE patients fulfilled the criteria for APS (17/20 for definitive and 3 for probable APS). There was a significant association between persistently present antiphospholipid antibodies and the CVE (OR, 4.62). No statistically significant difference was found in the CVE recurrence rate between APS-CVE and non-APS-CVE patients being treated mainly with acetyl salicylic acid. Antiphospholipid antibodies represent an independent risk factor for a CVE. In the first year after the CVE, antiplatelet therapy seemed to be sufficient in secondary CVE thromboprophylaxis in most APS patients.
Related Concept Videos
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Relative Risk
Integration of Synaptic Events
Transcription Factors
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Schwarzschild Radius and Event Horizon
The minimum speed required to launch a projectile from the surface of an object to which it is gravitationally bound so that it eventually escapes the object’s gravitational field is called the escape velocity. The escape velocity is independent of the mass of the object. Merging the idea of escape...

